Table 1 Clinical and pathological characteristics (n = 1000)
ISUP Grade | 1 | 2 | 3 | 4 | 5 | |
|---|---|---|---|---|---|---|
n = 163 | n = 481 | n = 219 | n = 39 | n = 98 | ||
Age | 67 | 66 | 68 | 67 | 69 | |
(46–77) | (45–79) | (50–80) | (56–79) | (48–77) | ||
Follow-up period | Months | 77 | 68.4 | 67.9 | 83 | 64.5 |
(4.9–135) | (0.7–132) | (4.6–129) | (6.6–122) | (16.6–121) | ||
PSA | ng/ml | 5.7 | 6.5 | 8 | 7 | 8.3 |
(1.1–19.5) | (0.4–50.9) | (3.1–81) | (2.5–17) | (4–82) | ||
Clinical T | cT1c, cT2 | 163 | 467 | 212 | 36 | 93 |
cT3a | 14 | 6 | 2 | 3 | ||
cT3b | 1 | 1 | 2 | |||
Pathological T | pT2a | 70 | 78 | 32 | 6 | 7 |
pT2b | 20 | 55 | 25 | 5 | 5 | |
pT2c | 71 | 244 | 69 | 13 | 27 | |
pT3a | 2 | 97 | 80 | 12 | 42 | |
pT3b | 7 | 13 | 3 | 17 | ||
Margin status | Positive | 25 (15%) | 193 (40%) | 108 (49%) | 9 (24%) | 44 (44%) |
Tertiary Gleason pattern 5 | 0/163 | 80/481 | 91/219 | 1/39 | ||
(0%) | (17%) | (42%) | (3%) |
